Skip to main content
Erschienen in: Medical Oncology 4/2015

01.04.2015 | Original Paper

Intensity-modulated radiotherapy and volumetric-modulated arc therapy have distinct clinical advantages in non-small cell lung cancer treatment

verfasst von: Jun Zhang, Xiao-Ling Yu, Guo-Feng Zheng, Fei Zhao

Erschienen in: Medical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

This study was conducted to compare the efficacy of intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) in delivering the planned dosage in the treatment of non-small cell lung cancer (NSCLC). Between September 2013 and March 2014, 125 NSCLC patients were randomly chosen and allocated to the IMRT group (n = 65) and VMAT group (n = 60). We compared multiple parameters such as target dose, organ dosimetry, monitor unit (MU) and time of therapy between IMRT and VMAT groups. The prescribed dose coverage of both planning techniques was 95 % of the planning target volumes (PTVs). PTV 95 % and homogeneous index in IMRT plan were greater than those in VMAT plan (both P < 0.05), while no significant difference in conformity index was observed (P > 0.05). The mean total lung V5 and V10 in VMAT group were markedly higher than those in IMRT group, but the V20, V30, and V40 in VMAT group were significantly lower (all P < 0.05), but no statistically significant difference was observed in V15 and V20 (P > 0.05). Furthermore, the planning spine and esophagus at risk volume showed no statistical significances in both groups (P > 0.05). MU of IMRT plan was about 4.2 % less than that of VMAT plan, which was statistically significant (P < 0.001). Both IMRT and VMAT had significant advantages in the treatment of NSCLC. The IMRT may be better for NSCLC patients with poor pulmonary function, and VMAT may be recommended for NSCLC patients with normal pulmonary function.
Literatur
1.
Zurück zum Zitat Yun F, Jia Y, Li X, Yuan L, Sun Q, Yu H, et al. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer. Int J Clin Exp Pathol. 2013;6:2112–20.PubMedCentralPubMed Yun F, Jia Y, Li X, Yuan L, Sun Q, Yu H, et al. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer. Int J Clin Exp Pathol. 2013;6:2112–20.PubMedCentralPubMed
2.
Zurück zum Zitat Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W. The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer. 2013;13:464.CrossRefPubMedCentralPubMed Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W. The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer. 2013;13:464.CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Chen WL, Kuo KT, Chou TY, Chen CL, Wang CH, Wei YH, et al. The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis. BMC Cancer. 2012;12:273.CrossRefPubMedCentralPubMed Chen WL, Kuo KT, Chou TY, Chen CL, Wang CH, Wei YH, et al. The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis. BMC Cancer. 2012;12:273.CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2013;39:252–60.CrossRefPubMed Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2013;39:252–60.CrossRefPubMed
6.
Zurück zum Zitat Zhu N, Gong Y, He J, Xia J, Chen X. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis. Yonsei Med J. 2013;54:1384–93.CrossRefPubMedCentralPubMed Zhu N, Gong Y, He J, Xia J, Chen X. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis. Yonsei Med J. 2013;54:1384–93.CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71:3–10.CrossRefPubMed Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71:3–10.CrossRefPubMed
8.
Zurück zum Zitat Wiezorek T, Brachwitz T, Georg D, Blank E, Fotina I, Habl G, et al. Rotational IMRT techniques compared to fixed gantry IMRT and tomotherapy: multi-institutional planning study for head-and-neck cases. Radiat Oncol. 2011;6:20.CrossRefPubMedCentralPubMed Wiezorek T, Brachwitz T, Georg D, Blank E, Fotina I, Habl G, et al. Rotational IMRT techniques compared to fixed gantry IMRT and tomotherapy: multi-institutional planning study for head-and-neck cases. Radiat Oncol. 2011;6:20.CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Lin H, Huang S, Deng X, Zhu J, Chen L. Comparison of 3D anatomical dose verification and 2D phantom dose verification of IMRT/VMAT treatments for nasopharyngeal carcinoma. Radiat Oncol. 2014;9:71.CrossRefPubMedCentralPubMed Lin H, Huang S, Deng X, Zhu J, Chen L. Comparison of 3D anatomical dose verification and 2D phantom dose verification of IMRT/VMAT treatments for nasopharyngeal carcinoma. Radiat Oncol. 2014;9:71.CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys. 2009;73:1187–95.CrossRefPubMed Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys. 2009;73:1187–95.CrossRefPubMed
11.
Zurück zum Zitat Ning ZH, Mu JM, Jin JX, Li XD, Li QL, Gu WD, et al. Single arc volumetric-modulated arc therapy is sufficient for nasopharyngeal carcinoma: a dosimetric comparison with dual arc VMAT and dynamic MLC and step-and-shoot intensity-modulated radiotherapy. Radiat Oncol. 2013;8:237.CrossRefPubMedCentralPubMed Ning ZH, Mu JM, Jin JX, Li XD, Li QL, Gu WD, et al. Single arc volumetric-modulated arc therapy is sufficient for nasopharyngeal carcinoma: a dosimetric comparison with dual arc VMAT and dynamic MLC and step-and-shoot intensity-modulated radiotherapy. Radiat Oncol. 2013;8:237.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Onal C, Arslan G, Parlak C, Sonmez S. Comparison of IMRT and VMAT plans with different energy levels using Monte-Carlo algorithm for prostate cancer. Jpn J Radiol. 2014;32:224–32.CrossRefPubMed Onal C, Arslan G, Parlak C, Sonmez S. Comparison of IMRT and VMAT plans with different energy levels using Monte-Carlo algorithm for prostate cancer. Jpn J Radiol. 2014;32:224–32.CrossRefPubMed
13.
Zurück zum Zitat Peters S, Schiefer H, Plasswilm L. A treatment planning study comparing Elekta VMAT and fixed field IMRT using the varian treatment planning system eclipse. Radiat Oncol. 2014;9:153.CrossRefPubMedCentralPubMed Peters S, Schiefer H, Plasswilm L. A treatment planning study comparing Elekta VMAT and fixed field IMRT using the varian treatment planning system eclipse. Radiat Oncol. 2014;9:153.CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Zhuang M, Zhang T, Chen Z, Lin Z, Li D, Peng X, et al. Advanced nasopharyngeal carcinoma radiotherapy with volumetric modulated arcs and the potential role of flattening filter-free beams. Radiat Oncol. 2013;8:120.CrossRefPubMedCentralPubMed Zhuang M, Zhang T, Chen Z, Lin Z, Li D, Peng X, et al. Advanced nasopharyngeal carcinoma radiotherapy with volumetric modulated arcs and the potential role of flattening filter-free beams. Radiat Oncol. 2013;8:120.CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Gong G, Wang R, Guo Y, Zhai D, Liu T, Lu J, et al. Reduced lung dose during radiotherapy for thoracic esophageal carcinoma: VMAT combined with active breathing control for moderate DIBH. Radiat Oncol. 2013;8:291.CrossRefPubMedCentralPubMed Gong G, Wang R, Guo Y, Zhai D, Liu T, Lu J, et al. Reduced lung dose during radiotherapy for thoracic esophageal carcinoma: VMAT combined with active breathing control for moderate DIBH. Radiat Oncol. 2013;8:291.CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Lu SH, Cheng JC, Kuo SH, Lee JJ, Chen LH, Wu JK, et al. Volumetric modulated arc therapy for nasopharyngeal carcinoma: a dosimetric comparison with TomoTherapy and step-and-shoot IMRT. Radiother Oncol. 2012;104:324–30.CrossRefPubMed Lu SH, Cheng JC, Kuo SH, Lee JJ, Chen LH, Wu JK, et al. Volumetric modulated arc therapy for nasopharyngeal carcinoma: a dosimetric comparison with TomoTherapy and step-and-shoot IMRT. Radiother Oncol. 2012;104:324–30.CrossRefPubMed
17.
Zurück zum Zitat Theunissen EA, Zuur CL, Yurda M, van der Baan S, Kornman AF, de Boer J, et al. Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study. J Otolaryngol Head Neck Surg. 2014;43:30.CrossRefPubMed Theunissen EA, Zuur CL, Yurda M, van der Baan S, Kornman AF, de Boer J, et al. Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study. J Otolaryngol Head Neck Surg. 2014;43:30.CrossRefPubMed
18.
Zurück zum Zitat Hakariya T, Obata S, Igawa T, Sakai H. Feasibility of simultaneous integrated boost IMRT (SIB-IMRT) for castration-resistant prostate cancer. Anticancer Res. 2014;34:4261–5.PubMed Hakariya T, Obata S, Igawa T, Sakai H. Feasibility of simultaneous integrated boost IMRT (SIB-IMRT) for castration-resistant prostate cancer. Anticancer Res. 2014;34:4261–5.PubMed
19.
Zurück zum Zitat Zhou X, Ou X, Xu T, Wang X, Shen C, Ding J, et al. Effect of dosimetric factors on occurrence and volume of temporal lobe necrosis following intensity modulated radiation therapy for nasopharyngeal carcinoma: a case-control study. Int J Radiat Oncol Biol Phys. 2014;90:261–9.CrossRefPubMed Zhou X, Ou X, Xu T, Wang X, Shen C, Ding J, et al. Effect of dosimetric factors on occurrence and volume of temporal lobe necrosis following intensity modulated radiation therapy for nasopharyngeal carcinoma: a case-control study. Int J Radiat Oncol Biol Phys. 2014;90:261–9.CrossRefPubMed
20.
Zurück zum Zitat Kim ES, Yeo SG. Volumetric modulated arc radiotherapy sparing the thyroid gland for early-stage glottic cancer: a dosimetrical analysis. Oncol Lett. 2014;7:1987–91.PubMedCentralPubMed Kim ES, Yeo SG. Volumetric modulated arc radiotherapy sparing the thyroid gland for early-stage glottic cancer: a dosimetrical analysis. Oncol Lett. 2014;7:1987–91.PubMedCentralPubMed
21.
Zurück zum Zitat Ma P, Wang X, Xu Y, Dai J, Wang L. Applying the technique of volume-modulated arc radiotherapy to upper esophageal carcinoma. J Appl Clin Med Phys. 2014;15:4732.PubMed Ma P, Wang X, Xu Y, Dai J, Wang L. Applying the technique of volume-modulated arc radiotherapy to upper esophageal carcinoma. J Appl Clin Med Phys. 2014;15:4732.PubMed
22.
Zurück zum Zitat Xiao L, Huang R, You K, Chang H, Qiu B, Xiao W, et al. Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2014;17:219–24.PubMed Xiao L, Huang R, You K, Chang H, Qiu B, Xiao W, et al. Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2014;17:219–24.PubMed
23.
Zurück zum Zitat Treutwein M, Hipp M, Koelbl O, Dobler B. Searching standard parameters for volumetric modulated arc therapy (VMAT) of prostate cancer. Radiat Oncol. 2012;7:108.CrossRefPubMedCentralPubMed Treutwein M, Hipp M, Koelbl O, Dobler B. Searching standard parameters for volumetric modulated arc therapy (VMAT) of prostate cancer. Radiat Oncol. 2012;7:108.CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Holt A, van Vliet-Vroegindeweij C, Mans A, Belderbos JS, Damen EM. Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: a comparison with intensity-modulated radiotherapy techniques. Int J Radiat Oncol Biol Phys. 2011;81:1560–7.CrossRefPubMed Holt A, van Vliet-Vroegindeweij C, Mans A, Belderbos JS, Damen EM. Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: a comparison with intensity-modulated radiotherapy techniques. Int J Radiat Oncol Biol Phys. 2011;81:1560–7.CrossRefPubMed
25.
Zurück zum Zitat Jiang X, Li T, Liu Y, Zhou L, Xu Y, Zhou X, et al. Planning analysis for locally advanced lung cancer: dosimetric and efficiency comparisons between intensity-modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT). Radiat Oncol. 2011;6:140.CrossRefPubMedCentralPubMed Jiang X, Li T, Liu Y, Zhou L, Xu Y, Zhou X, et al. Planning analysis for locally advanced lung cancer: dosimetric and efficiency comparisons between intensity-modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT). Radiat Oncol. 2011;6:140.CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Paci M, Sgarbi G, Ferrari G, De Franco S, Annessi V. Controversies over UICC-TNM classification of non-small cell lung cancer: model for a diagnostic path. Chest. 2002;122:754.CrossRefPubMed Paci M, Sgarbi G, Ferrari G, De Franco S, Annessi V. Controversies over UICC-TNM classification of non-small cell lung cancer: model for a diagnostic path. Chest. 2002;122:754.CrossRefPubMed
27.
Zurück zum Zitat Kim MJ, Yeo SG, Kim ES, Min CK, Se An P. Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer. Oncol Lett. 2013;5:840–4.PubMedCentralPubMed Kim MJ, Yeo SG, Kim ES, Min CK, Se An P. Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer. Oncol Lett. 2013;5:840–4.PubMedCentralPubMed
28.
Zurück zum Zitat Abo-Madyan Y, Aziz MH, Aly MM, Schneider F, Sperk E, Clausen S, et al. Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer. Radiother Oncol. 2014;110:471–6.CrossRefPubMed Abo-Madyan Y, Aziz MH, Aly MM, Schneider F, Sperk E, Clausen S, et al. Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer. Radiother Oncol. 2014;110:471–6.CrossRefPubMed
29.
Zurück zum Zitat Chan OS, Lee MC, Hung AW, Chang AT, Yeung RM, Lee AW. The superiority of hybrid-volumetric arc therapy (VMAT) technique over double arcs VMAT and 3D-conformal technique in the treatment of locally advanced non-small cell lung cancer—a planning study. Radiother Oncol. 2011;101:298–302.CrossRefPubMed Chan OS, Lee MC, Hung AW, Chang AT, Yeung RM, Lee AW. The superiority of hybrid-volumetric arc therapy (VMAT) technique over double arcs VMAT and 3D-conformal technique in the treatment of locally advanced non-small cell lung cancer—a planning study. Radiother Oncol. 2011;101:298–302.CrossRefPubMed
30.
Zurück zum Zitat Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009;93:226–33.CrossRefPubMed Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009;93:226–33.CrossRefPubMed
31.
Zurück zum Zitat Merrow CE, Wang IZ, Podgorsak MB. A dosimetric evaluation of VMAT for the treatment of non-small cell lung cancer. J Appl Clin Med Phys. 2013;14:4110. Merrow CE, Wang IZ, Podgorsak MB. A dosimetric evaluation of VMAT for the treatment of non-small cell lung cancer. J Appl Clin Med Phys. 2013;14:4110.
32.
Zurück zum Zitat Agapito J. On the possible benefits of a hybrid VMAT technique in the treatment of non-small cell lung cancer. Med Dosim. 2013;38:460–6.CrossRefPubMed Agapito J. On the possible benefits of a hybrid VMAT technique in the treatment of non-small cell lung cancer. Med Dosim. 2013;38:460–6.CrossRefPubMed
33.
Zurück zum Zitat Bertelsen A, Hansen O, Brink C. Does VMAT for treatment of NSCLC patients increase the risk of pneumonitis compared to IMRT?—a planning study. Acta Oncol. 2012;51:752–8.CrossRefPubMed Bertelsen A, Hansen O, Brink C. Does VMAT for treatment of NSCLC patients increase the risk of pneumonitis compared to IMRT?—a planning study. Acta Oncol. 2012;51:752–8.CrossRefPubMed
Metadaten
Titel
Intensity-modulated radiotherapy and volumetric-modulated arc therapy have distinct clinical advantages in non-small cell lung cancer treatment
verfasst von
Jun Zhang
Xiao-Ling Yu
Guo-Feng Zheng
Fei Zhao
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0546-6

Weitere Artikel der Ausgabe 4/2015

Medical Oncology 4/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.